BACKGROUND: We administered a single dose of influenza A/Vietnam/1203/2004 (H5N1, clade 1) vaccine to subjects who had received 2 doses of influenza A/Hong Kong/156/1997 (H5N1, clade 0) vaccine in 1998. METHODS: Thirty-seven subjects previously vaccinated with a baculovirus-expressed recombinant hemagglutinin A/Hong Kong/156/1997 vaccine in 1998 received a single intramuscular dose of 90 microg of inactivated subvirion A/Vietnam/1203/2004 vaccine in 2006. Serum antibody was measured before vaccination and 28 and 56 days after vaccination. Antibody responses were compared with those measured after one or two 90-microg doses in H5-naive subjects. RESULTS: On day 28 after a single dose, the geometric mean titer (GMT) of hemagglutination-inhibition antibody in primed subjects was 64.0 (95% confidence interval [CI], 37.8-108.5), with 68% responding (4-fold increase in antibody level to a titer of >or=1:40). In contrast, H5-naive subjects who received two 90-microg doses had a day 56 (28 days after the second dose) GMT of 27.7 (95% CI, 20.3-38.0), with only 43% responding. CONCLUSIONS: This study suggests that priming can result in immune responses to a single dose of an antigenically variant strain of H5N1 influenza virus and could be a useful strategy for pandemic control. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00240903.
BACKGROUND: We administered a single dose of influenza A/Vietnam/1203/2004 (H5N1, clade 1) vaccine to subjects who had received 2 doses of influenza A/Hong Kong/156/1997 (H5N1, clade 0) vaccine in 1998. METHODS: Thirty-seven subjects previously vaccinated with a baculovirus-expressed recombinant hemagglutinin A/Hong Kong/156/1997 vaccine in 1998 received a single intramuscular dose of 90 microg of inactivated subvirion A/Vietnam/1203/2004 vaccine in 2006. Serum antibody was measured before vaccination and 28 and 56 days after vaccination. Antibody responses were compared with those measured after one or two 90-microg doses in H5-naive subjects. RESULTS: On day 28 after a single dose, the geometric mean titer (GMT) of hemagglutination-inhibition antibody in primed subjects was 64.0 (95% confidence interval [CI], 37.8-108.5), with 68% responding (4-fold increase in antibody level to a titer of >or=1:40). In contrast, H5-naive subjects who received two 90-microg doses had a day 56 (28 days after the second dose) GMT of 27.7 (95% CI, 20.3-38.0), with only 43% responding. CONCLUSIONS: This study suggests that priming can result in immune responses to a single dose of an antigenically variant strain of H5N1influenza virus and could be a useful strategy for pandemic control. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00240903.
Authors: Robert B Belshe; Sharon E Frey; Irene Graham; Mark J Mulligan; Srilatha Edupuganti; Lisa A Jackson; Anna Wald; Gregory Poland; Robert Jacobson; Harry L Keyserling; Paul Spearman; Heather Hill; Mark Wolff Journal: J Infect Dis Date: 2011-01-31 Impact factor: 5.226
Authors: Andrea J Sant; Anthony T DiPiazza; Jennifer L Nayak; Ajitanuj Rattan; Katherine A Richards Journal: Immunol Rev Date: 2018-07 Impact factor: 12.988
Authors: Kawsar R Talaat; Catherine J Luke; Surender Khurana; Jody Manischewitz; Lisa R King; Bridget A McMahon; Ruth A Karron; Kristen D C Lewis; Jing Qin; Dean A Follmann; Hana Golding; Kathleen M Neuzil; Kanta Subbarao Journal: J Infect Dis Date: 2014-03-05 Impact factor: 5.226
Authors: Felix Geeraedts; Vinay Saluja; Wouter ter Veer; Jean-Pierre Amorij; Henderik W Frijlink; Jan Wilschut; Wouter L J Hinrichs; Anke Huckriede Journal: AAPS J Date: 2010-03-02 Impact factor: 4.009